|
|
|
|
|
Daunorubicin
drug data and news
Daunorubicin drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Daunorubicin | ||
| Brand Names/Synonyms | Acetyladriamycin; Anthracyline; Antibiotics From Streptomyces Coeruleorubidus; CCRIS 914; Cerubidin; Cerubidine; DM1; DRG-0155; Daunamycin; Daunarubicinum; Daunoblastin; Daunomycin; Daunomycin Hydrochloride; Daunomycin, Hydrochloride; Daunorrubicina; Daunorubicin; Daunorubicin Hcl; Daunorubicin Hydrochloride; Daunorubicin, Hydrochloride; Daunorubicine; Daunorubicinum [Inn-Latin]; Daunoxome; FI6339; HSDB 5095; Leukaemomycin C; Ondena; RUBIDOMYCIN; Rcra Waste No. U059; Rp 13057 Hydrochloride; Rubidomycin Hydrochloride; Rubomycin C; VS-103 | ||
| Indication | For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Daunorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Daunorubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Daunorubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific. | ||
| Mechanism Of Action | Daunorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Daunorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. | ||
| Daunorubicin News (When available) |
Select AIDS, cancer drugs to become cheaper Mar 2, 2006 Anthracyclines Linked with Damage to Blood Vessels Feb 24, 2006 The importance of coenzyme Q10 Feb 19, 2006 | ||
| Dosage Forms | POWDER FOR SOLUTION; SUSPENSION | ||
| Drug_Category | Antibiotics; Antineoplastic Agents; ATC:L01DB02 | ||
| Absorption | Not Available | ||
| Interactions |
Interactions for Daunorubicin: Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity. Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine. Cyclophosphamide used concurrently with Cerubidine may also result in increased cardiotoxicity. Dosage reduction of Cerubidine may be required when used concurrently with other myelosuppressive agents. Hepatotoxic medications, such as high-dose methotrexate, may impair liver function and increase the risk of toxicity. | ||
| Toxicity | LD50=20 mg/kg (mice, IV); LD50=13 mg/kg (rat, IV) | ||
| Organisms Affected | Not Available | ||
| Chemical IUPAC Name | 8-acetyl-10-(4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl)oxy-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione | ||
| Chemical Formula | C27H29NO10 | ||
| Molecular Weight | 527.52 g/mol | ||
| Smiles String | CC1C(C(CC(O1)OC2CC(CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)C)O)N)O | ||
| Melting Point | 208-209 °C | ||
| Water Solubility | 39.2 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 0.766 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic | ||
| Half Life | 18.5 hours | ||
| Protein Binding [%] | 97% binding-albumin | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Daunorubicin.html http://www.rxlist.com/cgi/generic2/daunorubicin.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00521 | ||
| CAS Registry Number | 20830-81-3 | ||
| KEGG Compound ID | C01907 | ||
| PubChem ID | SID:172470 | ||
| PharmGKB ID | PA449212 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2231420 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |